Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data-Reference-Cited by-同舟云学术

Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data

Published:2022-05 Issue:23 Volume:40 Page:3203-3209
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Wanlapakorn Nasamon,Suntronwong Nungruthai,Phowatthanasathian Harit,Yorsaeng Ritthideach,Thongmee Thanunrat,Vichaiwattana Preeyaporn,Auphimai Chompoonut,Wongsrisang Lakkhana,Klinfueng Sirapa,Sudhinaraset Natthinee,Poovorawan Yong

Funder

National Research Council of Thailand

Health Systems Research Institute

King Chulalongkorn Memorial Hospital

Chulalongkorn University

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference24 articles.

1. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial;Liu;Lancet,2021

2. CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial;Borobia;Lancet,2021

3. Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data;Shaw;Lancet,2021

4. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination;Barros-Martins;Nat Med,2021

5. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study;Hillus;Lancet Respir Med,2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand;Vaccine: X;2024-06

2. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with inactivated and adenoviral vectored SARS-CoV-2 vaccines – A prospective multi-center study;Heliyon;2024-01

3. Longitudinal Analysis of Neutralizing Antibodies Against SARS-CoV-1 and Different SARS-CoV-2 Strains in Breakthrough and Unvaccinated Covid-19 Patients in Thailand;2024

4. Modeling vaccination strategies with limited early COVID-19 vaccine access in low- and middle-income countries: A case study of Thailand;Infectious Disease Modelling;2023-12

5. Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose;Vaccine;2023-10